Table 6.
The development of other potential therapeutic strategies in Alzheimer’s disease.
| Compounds | Chemical class | Assignee | Patent number | Phases | Ref. |
|---|---|---|---|---|---|
| Mitochondrial therapy | |||||
| Latrepirdine | Tetracyclic pyrazinoindoles | Pfizer Inc., USA; Medivation Neurology, Inc., USA | WO039675A2 (2011) | Phase I | [135] |
| 16a | Indole, indoline derivatives | BarIlan University, Israel | WO150529 A2(2013) | Discovery | [136] |
| 17a | Chroman derivatives | Ampere Life Sciences, Inc., USA | US0267538 A1(2013) | Discovery | [137] |
| 18a | 4-(p-quinolyl)-2-hydroxybutanamide derivatives | Edison Pharmaceuticals, Inc., USA | US0289034 A1(2013) | Discovery | [138] |
| 19a | Catechol derivatives | Edison Pharmaceuticals, Inc., USA | WO174286 A1(2012) | Discovery | [139] |
| Neurotrophins | |||||
| SR57667 | Tetrahydropyridins | Sanofi-Aventis, France | WO025363 A1(1999) | Phase II | [140] |
| FK962 | Fluorobenzamide | Senju Pharmaceutical, Japan; Astellas Pharma Inc., Japan | WO133198A1(2008) | Phase II | [141] |
| T-817MA | Benzothiophene oxide derivative | Toyama Chemical Co., Ltd, Japan | WO145171A1(2009) | Phase II | [142] |
| 20a | Alkanone derivatives | Sanofi-Aventis, France | US20130303520 A1 | Discovery | [143] |